Treatment of the Patient after Myocardial Infarction

At the turn of the decade, the results of three major clinical trials concerned with the treatment of patients who have survived an acute myocardial infarction are being published. One of these, on the use of sulfinpyrazone, appears in this issue of the Journal. Two similar investigations of the use of aspirin are being presented almost simultaneously.1 , 2 When one considers the enormous number of post-infarction patients, the findings of these studies — indeed, of the vast body of information that has been amassed in recent years concerning treatment of these patients — deserve the most careful scrutiny.For convenience, let . . .